Journal of Multiple Sclerosis

ISSN - 2376-0389

Citations Report

Journal of Multiple Sclerosis : Citations & Metrics Report

Articles published in Journal of Multiple Sclerosis have been cited by esteemed scholars and scientists all around the world. Journal of Multiple Sclerosis has got h-index 10, which means every article in Journal of Multiple Sclerosis has got 10 average citations.

Following are the list of articles that have cited the articles published in Journal of Multiple Sclerosis.

  2020 2019 2018 2017 2016

Year wise published articles

6 3 9 20 33

Year wise citations received

43 50 42 54 44
Journal Impact Factor 2020 formula
IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year
Journal 5-year Impact Factor 2020 formula
Citations(2016 + 2017 + 2018 + 2019 + 2020)/
{Published articles(2016 + 2017 + 2018 + 2019 + 2020)}
Journal citescore
Citescorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3
Journal total citations count 337
Journal impact factor 3.58
Journal 5 years impact factor 3.28
Journal cite score 4.97
Journal h-index 10
Journal h-index since 2016 8
Important Citations

Khan M, Zahoor I, Haq EU (2015) Human Immunodeficiency Virus and Multiple Sclerosis Risk: Probing for a Connection. J Mult Scler 2(1000141): 376-0389.

Sánchez Morales C (2017) Alteraciones motoras, cognitivas y emocionales en la encefalomielitis autoinmune experimental.

Ludwig M, Turel AP, Zagon IS, McLaughlin PJ (2016) Take a look at the Recent articles.

Ludwig MD, Turel AP, Zagon IS, McLaughlin PJ (2016) Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Multiple Sclerosis Journal–Experimental, Translational and Clinical 2: 2055217316672242.

Ludwig MD, Turel AP, Zagon IS, McLaughlin PJ (2015) Treatment of clinically isolated syndrome and low dose naltrexone. Clin Case Reports Rev 1: 182-184.

McLaughlin PJ, Zagon IS (2015) Duration of opioid receptor blockade determines biotherapeutic response. Biochemical pharmacology 97: 236-46.

Charvet LE, Taub E, Cersosimo B, Rosicki C, Melville P (2015) The Montreal Cognitive Assessment (MoCA) in Multiple Sclerosis: Relation to Clinical Features. J Mult Scler 2: 2376-0389.

Contini C, Granieri E, Fainardi E, Stratton CW (2015) Role of Chlamydophila pneumoniae in the Pathogenesis of Chronic Cerebrospinal Venous Insuffiency in Patients with Multiple Sclerosis. J Mult Scler (Foster City) 2: 2376-0389.

Šalinović H (2016) Lijekovi koji modificiraju tijek bolesti-multipla skleroza (Doctoral dissertation, University of Zagreb. Faculty of Pharmacy and Biochemistry. Department of pharmacology.

Šalinović H (2016) DIPLOMSKI RAD.

Modi KK, Rangasamy SB, Dasarathi S, Roy A, Pahan K (2016) Cinnamon Converts Poor Learning Mice to Good Learners: Implications for Memory Improvement. Journal of Neuroimmune Pharmacology 11: 693-707.

Chen YF, Wang YW, Huang WS, Lee MM, Wood WG (2016) Trans-cinnamaldehyde, an essential oil in cinnamon powder, ameliorates cerebral ischemia-induced brain injury via inhibition of neuroinflammation through attenuation of iNOS, COX-2 expression and NFκ-B signaling pathway. Neuromolecular medicine 18: 322-233.

Ben-Zacharia AB (2015) Screening for Depression in Adult Patients with Multiple Sclerosis. J Mult Scler 2: 2376-0389.

Freiesleben S, Hecker M, Zettl UK, Fuellen G, Taher L (2016) Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms. Scientific Reports 6.

Galea I, Elwood E, Lim ZW, Naveed H (2016) Lymphopenia in treatment-naive relapsing multiple sclerosis. Neurology: Neuroimmunology & Neuroinflammation 11: 1-9.

Lim ZW, Elwood E, Naveed H, Galea I (2016) Lymphopenia in treatment-naive relapsing multiple sclerosis. Neurology-Neuroimmunology Neuroinflammation 3: e275.

Karim RM, Wang YF (2016) The Study Progress of B Cells and Neuroimmunological Diseases. J Neurol Neurophysiol 7: 369.

Giacomini E, Rizzo F, Etna MP, Cruciani M, Mechelli R (2017) Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing–remitting multiple sclerosis patients. Multiple Sclerosis Journal 1: 1352458517695892.

Deng J, Pennati A, Cohen JB, Wu Y, Ng S, Wu JH, Flowers CR, Galipeau J (2016) GIFT4 fusokine converts leukemic B cells into immune helper cells. Journal of translational medicine 14: 106.

Alexopoulos H, Biba A, Dalakas MC (2016) Anti-B-cell therapies in autoimmune neurological diseases: Rationale and efficacy trials. Neurotherapeutics 1: 20-33.

Relevant Topics